Fund
TCGX
Page built from the operations logged, not from a written profile. It says nothing about the fund's activity outside the scope of Bolus, which is health venture capital in Europe and the United States.
- Operations logged
- 3
- Lead
- 3
- New entries
- 0
- Follow ons
- 0
- Latest operation
- 11 August 2026
- Sectors
- Biotech
Operations
| Date | Company | Stage | Amount | Role |
|---|---|---|---|---|
| 11 Aug | Switzerland, Biotech | Series B | 152 M$ | Lead |
| 26 Jun | United States, Biotech | Series B | 330 M$ | Lead |
| 20 Feb | United States, Biotech | Series A | 175 M$ | Lead |
Co investors 15 funds crossed
- ARCH Venture Partners 1 operation
- Blackstone Multi-Asset Investing 1 operation
- Commodore Capital 1 operation
- Droia Ventures 1 operation
- EQT Life Sciences 1 operation
- Fairmount 1 operation
- Kalehua Capital 1 operation
- Life Sciences at Goldman Sachs Alternatives 1 operation
- Medicxi 1 operation
- Omega Funds 1 operation
- Paragon Therapeutics 1 operation
- Perceptive Advisors 1 operation
- RA Capital Management 1 operation
- Venrock Healthcare Capital Partners 1 operation
- Wellington Management 1 operation
Funds that appeared in the same rounds, in any capacity. Geographies logged: Switzerland, United States.